COSOPT 20 mg/ml + 5 mg/ml, eye drops, solution
*Company:
Santen UK LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 13 April 2023
File name
spc-cosopt-md-en-ie_Implem 20230228.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Remove text re Ocumeter+ bottle from sections 4.2 & 6.5 as no longer marketed.
Updated on 18 January 2023
File name
spc-cosopt-md-en-ie-APPR 20220202.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 07 February 2022
File name
spc-cosopt-md-en-ie-APPR 20220202.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
6.3 Shelf life
3 years.2
COSOPT should be used no longer than 28 days after first opening the container.
..............
10. DATE OF REVISION OF THE TEXT
02 February 2022October 2021
Updated on 13 October 2021
File name
pil-cosopt-md-en-uk-ie-APPR-20211010_Noto.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Section 2
Warnings and precautions
..
When COSOPT is instilled into the eye, it may affect the entire body.
If you wear soft contact lenses, you should consult your doctor before using this medicine.
ChildrenUse in children
There is limited experience with COSOPT in infants and children.
ElderlyUse in elderly
In studies with COSOPT, the effects of this medicine were similar in both elderly and younger patients.
.....
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Askthis medicine.any
Use in pregnancy
Do not use COSOPT if you are pregnant unless your doctor considers it necessary.
Use in breast-feeding
Do not use COSOPT if you are breast-feeding. Timolol may get into breastmilk. Ask your doctor for advice before taking any medicine during breast-feeding.your milk
Driving and using machines
No studies on the effects on the ability to drive or use machines have been performed. There are side effects associated with COSOPT, such as blurred vision, which may affect your ability to drive and/or operate machinery. Do not drive or operate machinery until you feel well or your vision is clear.
COSOPT contains benzalkonium chloride
This medicine contains approximately 0.002 mg benzalkonium chloride in each drop which is equivalent to 0.075 mg/ml.If you wear
Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should , youremove contact lenses before using this medicine and put them back 15 minutes afterwards.consult
Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor. before using COSOPT (the preservative benzalkonium chloride may possibly discolour the lenses).
Section 4 side effects
Explanation of frequency added next to relevant paragraph instead as table at top of section.
Northern Ireland added after UK in country list
This leaflet was last revised in May 2021.February
Updated on 13 October 2021
File name
spc-cosopt-md-en-ie-APPR-20211010.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 2
….
Each ml contains 22.26 mg of dorzolamide hydrochloride corresponding to 20 mg dorzolamide and 6.83 mg of timolol maleate corresponding to 5 mg timolol.
xcipientE with known effect: sBenzalkonium chloride 0.075 mg/ml.
One ml of eye drops solution contains 0.075 mg benzalkonium chloride and one drop contains about 0.002 mg of benzalkonium chloride.
For the full list of excipients, see section 6.1.
Section 4.4
…..
Benzalkonium chloride
Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.
Contact Lens Use
OSOPT contains benzalkonium chloride as preservative. Contact lenses should be removed prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.CThis medicinal product contains the preservative benzalkonium chloride, which may cause eye irritation. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.
Paediatric population
See section 5.1.
Section 10
February 2020 October 2021
Updated on 07 April 2021
File name
pil-cosopt-md-en-ie-uk APPR 20210313 Noto.pdf
Reasons for updating
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
This leaflet was last revised in February 2021.March 2020
Updated on 24 March 2020
File name
pil-cosopt-md-en-ie-uk-20200316.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Manufacturer:
Santen Oy
, Niittyhaankatu 20 33720
Kelloportinkatu 1, 33100 Tampere
....
This leaflet was last revised in March 2020.November 2019
Updated on 14 February 2020
File name
pil-cosopt-md-en-uk-ie-Noto-APPR 20200210.pdf
Reasons for updating
- XPIL Updated
Free text change information supplied by the pharmaceutical company
XPIL pdated inline with leaflet changes
Section 4 Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You can usually carry on taking the drops, unless the effects are serious. If you're worried, talk to a doctor or pharmacist. Do not stop using COSOPT without speaking to your doctor.
Serious side effects:
If you experience any of the following side effects, stop using this medicine and seek immediate medical advice as these could be signs of a reaction to the medicine.
Generalised allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs, and can obstruct the airways which may cause difficulty swallowing, orshortness of breath, hives or itchy rash, localised and generalised rash, itchiness, severe sudden life-threatening allergic reaction. breathing
You can usually carry on taking the drops, unless the effects are serious. If you're worried, talk to a doctor or pharmacist. Do not stop using COSOPT without speaking to your doctor.
Frequency Uncommon – text below changed
shortness of breath,difficulty breathing (dyspnoea)
Frequency Rare - text below changed
…forceful heartbeat that may be rapid or irregular (palpitations)…palpitations (a quicker and/or irregular heartbeat)
Frequency not known- text below added:
… hallucination and foreign body sensation in eye (feeling that there is something in your eye).
Reporting of side effects
HPRA postal address, phone and fax numbers deleted
Section 6
This leaflet was last revised in November 2019.June 2018
Updated on 14 February 2020
File name
pil-cosopt-md-en-uk-ie-Noto-APPR 20200210.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
- Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You can usually carry on taking the drops, unless the effects are serious. If you're worried, talk to a doctor or pharmacist. Do not stop using COSOPT without speaking to your doctor.
Serious side effects:
If you experience any of the following side effects, stop using this medicine and seek immediate medical advice as these could be signs of a reaction to the medicine.
Generalised allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs, and can obstruct the airways which may cause difficulty swallowing, orshortness of breath, hives or itchy rash, localised and generalised rash, itchiness, severe sudden life-threatening allergic reaction. breathing
You can usually carry on taking the drops, unless the effects are serious. If you're worried, talk to a doctor or pharmacist. Do not stop using COSOPT without speaking to your doctor.
Frequency Uncommon – text below changed
shortness of breath,difficulty breathing (dyspnoea)
Frequency Rare - text below changed
…forceful heartbeat that may be rapid or irregular (palpitations)…palpitations (a quicker and/or irregular heartbeat)
Frequency not known- text below added:
… hallucination and foreign body sensation in eye (feeling that there is something in your eye).
Reporting of side effects
HPRA postal address, phone and fax numbers deleted
Section 6
This leaflet was last revised in November 2019June 2018
Updated on 14 February 2020
File name
spc-cosopt-md-en-ie-APPR 20200213.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
SPC Section 4.8 - added:
Psychiatric disorders: hallucination
Eye disorders: foreign body sensation in eye
Cardiac disorders: palpitations
Respiratory, thoracic, and mediastinal disorders: dyspnoea
Reporting of suspected adverse reactions
Deleted: HPRA postal address, phone and fax numbers
SPC section 10 - date changed:
November 2018 February 2020
Updated on 20 September 2019
File name
pl-Noto only uk_ie.pdf
Reasons for updating
- XPIL Updated
Updated on 20 September 2019
File name
pl-Noto only uk_ie.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
Updated on 20 September 2019
File name
pl-Noto only uk_ie.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
Free text change information supplied by the pharmaceutical company
Changes have been made due to introduction of product in new new bottle
Updated on 09 January 2019
File name
cosopt-md-ie-pil-ocumeter APPR20181121.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 09 January 2019
File name
spc-cosopt-md-en-ie-APPR20181121.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.2
.......
Method of administration
- Wash your hands
- Open the container. Take special care that the tip of the dropper container does not touch your eye, the skin around your eye or your fingers.
- Tilt your head backwards and hold the container upside down over the eye.
- Pull the lower eyelid downwards and look up. Hold and gently squeeze the container on the flattened sides of the container and let one drop fall into the space between the lower eyelid and the eye.
- Press a finger into the corner of your eye, by the nose, or close your eyelids for 2 minutes. This helps to stops the medicine from getting into the rest of the body.
- Repeat steps 3 to 5 with the other eye if instructed to do so by your doctor.
- Put the cap back on and close the container tightly.
[OCUMETER PLUS containers only]
- Before using the medication for the first time, be sure the Safety Strip on the front of the container
is unbroken. A gap between the containerbottleand the cap is normal for an unopened containerbottle.bottle
....................
Section 6.5
6.5 Nature and contents of container
COSOPT containers contain 5 ml of solution. Two alternate containers may be marketed.
White translucent low-density polyethylene container, a transparent dropper tip and a white cap
or
OCUMETER Plus Ophthalmic Dispenser consistingThe of a translucent, high‑density polyethylene container with a sealed dropper tip, a flexible fluted side area which is depressed to dispense the drops, and a 2‑piece cap assembly. The 2‑piece cap mechanism punctures the sealed dropper tip upon initial use, then locks together to provide a single cap during the usage period. Tamper evidence is provided by a safety strip on the container label.consists The OCUMETER Plus Ophthalmic Dispenser contains 5 ml of solution.
COSOPT is available in the following packaging configurations:
1 x 5 ml (single 5 ml container)s
3 x 5 ml (three 5 ml containers)
6 x 5 ml (six 5 ml containers)
Not all pack sizes may be marketed.
Section 10
November 2018 July 2015
Updated on 04 January 2016
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 January 2016
File name
PIL_16586_351.pdf
Reasons for updating
- New PIL for new product